What Caused My Cancer? - Get Legal Help for Cancer Caused by Toxic Exposure

Dupixent T-Cell Lymphoma Lawsuit

Were You Diagnosed with Cutaneous T-Cell Lymphoma After Taking Dupixent?

Studies show Dupixent users face up to 4.5x higher risk of cutaneous T-cell lymphoma (CTCL). The FDA is investigating after receiving over 300 adverse event reports of lymphoma among Dupixent users.

If you used Dupixent for eczema, asthma, or other conditions and were later diagnosed with CTCL or another T-cell lymphoma, you may be entitled to significant compensation.

No Win, No Fee | Free Consultation | Confidential

What is Dupixent and What Are the Risks?

Dupixent (dupilumab) is a prescription injection manufactured by Sanofi and Regeneron, first approved by the FDA in 2017. It is commonly prescribed for patients with moderate-to-severe inflammatory conditions including:

Atopic dermatitis (eczema)
Moderate-to-severe asthma
Chronic sinusitis with nasal polyps
Eosinophilic esophagitis
Prurigo nodularis

FDA Investigation Underway

In March 2025, the FDA placed Dupixent on its quarterly FAERS "Potential Signals" list for cutaneous T-cell lymphoma, confirming it is "evaluating the need for regulatory action" after receiving over 300 adverse event reports of lymphoma among Dupixent users.

Do You Qualify for Compensation?

You may qualify if:

✓You were prescribed Dupixent (dupilumab) for any approved condition
✓You were diagnosed with cutaneous T-cell lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome, or another T-cell lymphoma
✓Your cancer diagnosis came after starting Dupixent treatment
✓You have medical records documenting your Dupixent use and cancer diagnosis

Current Dupixent Litigation Status

Lawsuits Are Being Filed Now

In October 2025, the first Dupixent wrongful death lawsuit was filed in Tennessee, marking a major development in the litigation against Sanofi and Regeneron. The case involves a woman who died from T-cell lymphoma just months after beginning Dupixent injections.

Early-Stage Litigation

Currently, there is no class action or multidistrict litigation (MDL). Cases are being filed individually. Attorneys across the country are investigating claims and building cases as more evidence emerges linking Dupixent to cancer.

What This Means For You:

Filing early may position your case favorably
More lawsuits strengthen the overall litigation
Evidence is being gathered and preserved
MDL consolidation may occur as cases grow

Manufacturers Face Scrutiny:

Sanofi and Regeneron co-market Dupixent
$14.1 billion in sales in 2024 alone
Failure to warn patients of cancer risk
FDA now actively investigating

Note: Because litigation is in early stages, settlement amounts are not yet established. However, similar pharmaceutical lawsuits have resulted in significant compensation for victims.

No Win, No Fee

Our network attorneys work on contingency. You pay nothing unless you receive compensation for your injuries.

Important Information About Dupixent

Drug Status (As of December 2025):

•Dupixent has NOT been recalled by the FDA or manufacturers
•The medication remains FDA-approved for multiple conditions
•FDA is actively evaluating whether new cancer warnings should be added
•Patients currently taking Dupixent should consult their doctor before making changes

If you are currently taking Dupixent: Do not stop taking any medication without first consulting your healthcare provider. Discuss any concerns about cancer risk with your doctor. If you notice unusual skin changes, persistent rashes, or other concerning symptoms, seek medical attention promptly.

Scientific Research & Authoritative Sources

The information on this page is based on peer-reviewed research and regulatory findings:

Journal of the American Academy of Dermatology (2024)

Dupilumab therapy and CTCL risk in atopic dermatitis patients

FDA Adverse Event Reporting System (FAERS)

FDA Adverse Event Reporting System Public Dashboard

European Respiratory Journal

Ma et al. study on dupilumab and T-cell lymphoma risk in asthma patients (2025)

Dermatologic Therapy

Retrospective cohort analysis of CTCL risk in dupilumab-treated patients

This page is for informational purposes only and does not constitute legal or medical advice. Consult with a qualified attorney for case-specific legal guidance and your healthcare provider for medical decisions.